Health Care·Biotechnology·$28.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.50 | N/A | -2.32% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.50 | N/A | -2.32% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current financial performance but remains focused on future growth opportunities. They did not provide specific guidance for the upcoming quarters.
Management acknowledged challenges in achieving profitability.
They emphasized a focus on long-term growth despite current setbacks.
Natera's earnings report shows a larger-than-expected loss per share, which may raise concerns among investors about profitability. However, the stock rose by 4.08%, likely due to market optimism or other factors not directly tied to the earnings results. The lack of revenue figures and guidance may leave investors uncertain about the company's near-term performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MONOLITHIC PWR SYS I
Aug 1, 2022